Fortress Biotech Announces Rare Pediatric Disease Designation for CUTX-101 for the Treatment of Menkes Disease

NEXT STORY
Global Antifungal Drugs Market is Expected to Reach USD 13.87 Billion By 2026 : Fior Markets
PREV STORY
TYME and The Joseph Ahmed Foundation Announce First Patient Dosed in Phase II (HopES) Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with High-Risk Sarcomas
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

BioNTech SE Provides Update on Corporate Progress and Third Quarter 2019 Financial Results

author_avatar
NASDAQ Market News

FIT Biotech Oy: FIT Biotech webcasts the company half-year financial report on September 6th 2018, at 10.00 AM.

FIT Biotech Oy                                                                                               Press Release July 3rd 2018, 08.30 EET FIT Biotech webcasts the ...

author_avatar
NASDAQ Market News

Guy Goodwin joins COMPASS Pathways as Chief Medical Officer

author_avatar
NASDAQ Market News